No Data
HIGHTIDE-B (02511): Gao Liping has been appointed as the joint company secretary.
HIGHTIDE-B (02511) has announced that due to the need to allocate more time to other work arrangements, Yu Li has submitted...
HighTide Therapeutics to Cooperate on Chronic Diseases, Longevity, Anti-Aging With SSY Group
Express News | HighTide Therapeutics - Unit Entered Into Strategic Co-Operation Framework Agreement With Shijiazhuang No. 4 Pharmaceutical
SSY GROUP (02005.HK) has signed a framework agreement with Junshentai Pharmaceutical for joint research and development.
On December 19, Gelonghui reported that SSY GROUP (02005.HK) announced that its wholly-owned subsidiary, Shijiazhuang Four Pharmaceuticals Co., Ltd., has entered into a strategic cooperation framework agreement with HIGHTIDE-B (02511.HK) and its wholly-owned subsidiary ("Partner"). The agreement aims to combine the group's extensive experience in active screening, formulation development, achievement transformation, quality, and cost control, along with HIGHTIDE-B's unique advantages in the field of natural product multi-system collaborative innovation, to tackle industry challenges and provide breakthrough solutions for Global metabolic diseases and longevity anti-aging.
HIGHTIDE-B (02511.HK) has appointed DaHua Ma Shi Yun as its auditor.
On December 11, Gelonghui reported that HIGHTIDE-B (02511.HK) announced that Ernst & Young has resigned as the company's auditor, effective from December 11, 2024, due to the company and Ernst & Young failing to reach an agreement on the proposed audit fees for the year ending December 31, 2024. The Board of Directors further announced that after a recommendation by the audit committee, it has resolved to appoint Deloitte Touche Tohmatsu CPA Ltd. as the new auditor of the company, effective from December 11, 2024, to fill the temporary vacancy left by Ernst & Young's resignation, and it is expected that Deloitte will serve until the company is due.
HIGHTIDE-B: 2024 Interim Report
No Data